Acrux delivers sweet medicine

The biotech company posted a boost of sales from its testosterone treatment product and is well positioned for its milestone payment from Eli Lilly this year.

Shares in Acrux (ACR) jumped 1.4% to $3.55 this morning on news of a material increase in sales of its spray on testosterone treatment.

Pharmaceutical giant Eli Lily, which is the exclusive distributor of Acrux’s Axiron, reported sales of $US47 million in the June quarter, or a 27% increase from the previous quarter and a three-fold increase in nine months.

Total sales for Axiron reached $US124 million in the 2012-13 financial year and royalties paid to Acrux has jumped to $14 million from $6 million in the previous year.

Royalties are calculated as a percentage of sales and Acrux expects this percentage to increase in the current financial year as sales of Axiron hits certain milestones.

Speaking of milestones, Acrux will receive a $US25 million milestone payment from Eli Lily if worldwide net sales of Axiron exceed $US100 million in the 2013 calendar year. Acrux only needs $US16 million in additional sales from now to the end of the December to achieve this milestone.

Acrux is part of the Uncapped 100.

Want access to our latest research and new buy ideas?

Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.

Sign up for free

Related Articles